Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$899K Buy
2,556
+3
+0.1% +$1.07K 0.03% 178
2025
Q4
$836K Buy
2,553
+190
+8% +$60.3K 0.03% 177
2025
Q3
$667K Sell
2,363
-294
-11% -$85.3K 0.03% 172
2025
Q2
$742K Buy
2,657
+1,422
+115% +$403K 0.04% 171
2025
Q1
$385K Buy
1,235
+267
+28% +$78.8K 0.02% 191
2024
Q4
$252K Buy
968
+11
+1% +$3.26K 0.01% 222
2024
Q3
$308K Hold
957
0.02% 197
2024
Q2
$299K Sell
957
-20
-2% -$5.88K 0.02% 185
2024
Q1
$278K Buy
977
+20
+2% +$5.85K 0.02% 188
2023
Q4
$276K Hold
957
0.02% 175
2023
Q3
$257K Sell
957
-5
-0.5% -$1.25K 0.02% 166
2023
Q2
$214K Sell
962
-116
-11% -$26.9K 0.02% 179
2023
Q1
$261K Buy
1,078
+271
+34% +$66.5K 0.02% 163
2022
Q4
$212K Buy
+807
New +$216K 0.02% 161

Other funds holding AMGN

GM Advisory Group's AMGN Position: Q1 2026 in Review

GM Advisory Group increased its Amgen (AMGN) stake by 0.12% in Q1 2026, buying an estimated $1.07K and bringing the position to 2,556 shares worth $899K. The position accounts for 0.03% of the portfolio, ranked #178.

GM Advisory Group first reported a position in AMGN in Q4 2022 and has held it in 14 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • GM Advisory Group held 2,556 shares of Amgen worth $899K as of Q1 2026.
  • GM Advisory Group bought 3 Amgen shares in Q1 2026, an estimated $1.07K.
  • Amgen made up 0.03% of GM Advisory Group's portfolio in Q1 2026, its #178 holding.
  • GM Advisory Group first reported a position in Amgen in Q4 2022 and has held it in 14 quarters since.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on GM Advisory Group's 13F filing for Q1 2026, filed 28 Apr 2026.